Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
A biliary tract cancer trial hits on response rate, but survival data will be key.
AACR approaches, along with ASCO abstract titles.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
